Efficacy of intracavitary administration of cyclophosphamide, interleukin-2 and lymphokine activated killer cells against established intraperitoneal tumor.
In an established intraperitoneal tumor modell combination of chemo- and immunotherapy was tested in mice and shown to be superior to either treatment modell alone. This combination treatment is shown to prolong survival significantly in animals massively inoculated with tumor cells.
Eggermont
A M
AM
Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland.
Sugarbaker
P H
PH
D000818:Animals; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D007116:Immunization, Passive / Q000379:methods*; D007274:Injections, Intraperitoneal; D007376:Interleukin-2 / Q000008:administration & dosage*; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation*; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D010534:Peritoneal Neoplasms / Q000628:therapy*; D012513:Sarcoma, Experimental / Q000628:therapy*
D007376:Interleukin-2; D003520:Cyclophosphamide